Cyclo Price To Sales Ratio from 2010 to 2024
| CYTH Stock | USD 0.68 0.05 6.85% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 24.12125888 | Current Value 25.33 | Quarterly Volatility 16.70157496 |
Check Cyclo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.3 K, Interest Expense of 181.7 K or Total Revenue of 995.2 K, as well as many indicators such as Price To Sales Ratio of 25.33, Dividend Yield of 0.0 or PTB Ratio of 7.66. Cyclo financial statements analysis is a perfect complement when working with Cyclo Therapeutics Valuation or Volatility modules.
Cyclo | Price To Sales Ratio |
Latest Cyclo Therapeutics' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Cyclo Therapeutics over the last few years. Price to Sales Ratio is figured by comparing Cyclo Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cyclo Therapeutics sales, a figure that is much harder to manipulate than other Cyclo Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Cyclo Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 17.20 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Cyclo Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 19.09 | |
| Geometric Mean | 12.44 | |
| Coefficient Of Variation | 87.49 | |
| Mean Deviation | 12.07 | |
| Median | 18.13 | |
| Standard Deviation | 16.70 | |
| Sample Variance | 278.94 | |
| Range | 62.7082 | |
| R-Value | 0.36 | |
| Mean Square Error | 262.41 | |
| R-Squared | 0.13 | |
| Significance | 0.19 | |
| Slope | 1.33 | |
| Total Sum of Squares | 3,905 |
Cyclo Price To Sales Ratio History
About Cyclo Therapeutics Financial Statements
Investors use fundamental indicators, such as Cyclo Therapeutics' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Cyclo Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 24.12 | 25.33 |
Currently Active Assets on Macroaxis
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:Check out the analysis of Cyclo Therapeutics Correlation against competitors. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.